Intrinsic Value

The intrinsic value of Paul Hartmann AG (PHH2) under the Base Case is 199 EUR per share. Compared with the current market price of 192.5 EUR, the stock appears Undervalued by 3% .

The intrinsic value is calculated using the DCF method. The model mostly extends the recent record: revenue grows about 2% a year over the next five years, against 0% over the last five, and net margin stays near last year's 2.5%. If net margin stayed at its five-year average of 2.8%, the estimate would be about €176.

Do our valuations actually work? See backtest results .

PHH2 Intrinsic Value
€199
Undervaluation 3%
Intrinsic Value
Price €192.5

PHH2 is valued in line with its history. A discount of this size has been typical over the past 5 years.

Monitor PHH2
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €159.2
Get notified when the price drops into your buy zone
Intrinsic Value €199
Current Price €192.5
Margin of Safety 20% €159.2
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to PHH2

Fundamental Analysis

What Paul Hartmann Does

Health Care

Paul Hartmann AG makes medical and hygiene products that people use in hospitals, clinics, care homes, and at home. Its core products include wound dressings, bandages, wound cleansing items, incontinence products, surgical supplies, and disinfection products. The company also sells some items directly to consumers through pharmacies and other retail channels.

Headquarters
Germany DE
Employees
10 066
IPO date
Jan 1, 2003
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Paul Hartmann AG

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one PHH2 stock?

The intrinsic value for Paul Hartmann AG (PHH2) under the Base Case is 199 EUR.

Is PHH2 stock undervalued or overvalued?

Compared with the current market price of 192.5 EUR, the stock appears Undervalued by 3% .

Back to Top